
Cabaletta Bio, Inc.
NASDAQ:CABA
Overview | Financials
Company Name | Cabaletta Bio, Inc. |
Symbol | CABA |
Currency | USD |
Price | 1.19 |
Market Cap | 60,384,289 |
Dividend Yield | 0% |
52-week-range | 0.986 - 13.5 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Steven A. Nichtberger M.D. |
Website | https://www.cabalettabio.com |
An error occurred while fetching data.
About Cabaletta Bio, Inc.
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD